Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
NEW YORK — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest restructuring efforts were announced by 23andMe ...
South SF-based genetic testing company laying off 40% of workforce
23andMe, a popular South San Francisco-based genetic testing company, is laying off 40% of its workers after struggling with dismal earnings and a chaotic data breach. The company is scrapping approximately 200 employees, 23andMe announced in a Monday news release, which is expected to save the business more than $35 million.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company ...
23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies ...
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
A big data breach and deepening financial woes have sparked new concerns about the 23andMe's ability to protect the personal ...
23andMe is actively exploring all strategic options in parallel with discontinuing its therapeutics division. 23andMe ...
The genetic testing company 23andMe is cutting 40% of its workforce and ending its therapeutics program as its stock price ...
More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback